We recently compiled a list of 10 Best Young Stocks To Buy Now. In this article, we will look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ranks among the best young stocks to buy now.
Market Uncertainty to Remain Until Elections
A broader market trend observed ever since the Fed announced its September cut rate has been the volatility in the performance of small-caps. However, despite the continuous positive momentum, small-caps have not kept pace with more speculative assets, which experienced significant growth. This trend raises questions about potential implications for monetary policy and its impact on productive economic activities.
Smaller companies often benefit during periods of profit recovery, particularly when accompanied by supportive monetary policies. The prevailing trend among investors, however, still favors larger companies, even as mega-cap stocks exhibit slower growth and higher valuations compared to their smaller counterparts. Analysts maintain their stance on a balanced approach when it comes to investing in mega-caps, or even small-caps, setting the stage for a closer look at top-performing investments in the current year.
However, Stephanie Link, Chief Investment Strategist and Portfolio Manager at Hightower, recently expressed confidence in a soft landing for the economy despite market volatility, joining CNBC on September 21. This highlights a contrasting perspective amidst market volatility and uncertainty. While there are concerns regarding the performance of small-cap stocks and their ability to keep pace with larger, more speculative assets, Link’s optimism suggests that the economy may stabilize without entering a recession, again encouraging a balanced approach to investing.
Link highlighted the importance of confidence. She believes that the Fed is skillfully guiding the economy towards a soft landing, even amidst the expected market fluctuations before the elections.
Just 3 weeks ago, the S&P 500 had dropped by 4%. Still, it rebounded by 4% the following week. It rose another 1% last week, reaching new highs, and expressed optimism about buying opportunities during any market weakness, citing better-than-expected economic growth driven by recent data, including improved retail sales and manufacturing figures, as well as a decline in weekly jobless claims to a 4-month low. This positive economic backdrop supports an estimated growth rate of 2.9%, which is expected to benefit corporate earnings.
The tech sector has recently outperformed others. Link noted a broadening market trend over the past couple of months, indicating that while tech has taken the lead, other sectors such as financials, industrials, materials, and discretionary stocks are also showing strength. She advised investors to remain selective in their choices amidst ongoing volatility.
When discussing specific investment picks, Link highlighted ExxonMobil as a key choice. Despite projections indicating a 64% year-over-year decline in earnings for refining and marketing companies in Q3 and an 11% drop in production, Link believes this company is extremely cheap at a price-to-earnings ratio of approximately 13 times its estimate. She expects it to triple its production in exploration and production (E&P) and aims for organic growth of 10% between now and 2027. Upcoming catalysts include an analyst meeting scheduled for December 11th and several projects that are expected to generate $4 billion in earnings.
While touching on geopolitical factors affecting oil prices, particularly regarding the Middle East, Link suggested that much of this has already been factored into oil market prices and expressed confidence that the American oil and gas corporation would remain profitable even at lower oil prices, generating substantial profits at $30 per barrel and significantly higher returns at $70 per barrel through dividends and share buybacks.
When asked about the Department of Energy’s plans to refill the petroleum reserve at prices below $70 per barrel, Link dismissed this as irrelevant noise. Instead, she emphasized focusing on where companies are generating profits overall rather than getting distracted by short-term fluctuations.
The interplay between economic indicators, sector performance, and geopolitical factors continues to shape investment strategies as stakeholders prepare for future developments, especially as we see that stock performance can still not be accurately measured. On September 26, Tom Lee, Fundstrat Global Advisors managing partner and head of research, joined CNBC’s ‘Closing Bell’ to address the current state of the stock market following the Fed’s recent interest rate cuts.
Since the Fed implemented a significant rate reduction, the market has seen limited movement, with notable activity only occurring last Thursday. Tom Lee explained that the Fed’s actions have initiated an easing cycle, which historically tends to yield positive outcomes for the market 3-6 months down the line. However, he cautioned that stock performance in the immediate future remains uncertain due to ongoing repositioning ahead of the upcoming election in 40 days.
The conversation further explored whether the impending election would disrupt a favorable scenario for stocks to benefit from a post-Fed rally. Lee suggested that while this situation might delay market gains, it is not entirely negative. He noted that many wealth managers and family offices are hesitant to commit capital until after Election Day, preferring to wait until that event is behind them. He expressed optimism about a potential surge in stock prices following the election, stating that November and December typically see strong rallies in election years, especially when markets have already gained more than 10% in the first half of the year.
When discussing investor sentiment regarding the economy and the Fed’s capabilities, Lee indicated that so far, things look promising. He highlighted an upcoming Core Personal Consumption Expenditures (PCE) report expected on Friday, which could confirm that inflation is no longer a pressing concern. However, he noted a significant number of investors believe we may already be in a recession. For investor sentiment to shift back toward a soft landing perspective, evidence must exceed expectations.
Regarding a comment on recent target adjustments for the S&P 500, mentioning Brian Belski’s increase of his target to the highest on Wall Street, Lee acknowledged the potential upside in the next 3-6 months, expressing skepticism about setting aggressive targets like 6,000 for the S&P 500 at this time due to current valuations not being particularly low and having already experienced significant gains. He conveyed confidence in longer-term prospects but indicated caution regarding immediate investments.
As for small-cap stocks represented by the Russell 2000 index, Lee acknowledged some profit-taking after a strong week but maintained that such fluctuations are typical during bottoming phases. He drew parallels to previous market recoveries, such as energy stocks in 2021, suggesting that while current movements may feel erratic, they signal a multi-year growth opportunity for small caps.
The discussion also addressed concerns regarding overcrowded sectors within the market. Some analysts have noted that various sectors like industrials and utilities have reached or are trading near highs, prompting some investors to seek better value in bonds instead. However, Lee argued that equities offer inflation protection and capital appreciation potential that bonds typically do not provide. He emphasized that there are still numerous attractive opportunities within equities.
As the stock market is expected to remain volatile, primarily due to the upcoming elections on top of economic uncertainty, there is potential for growth in the coming months and investors should exercise caution and carefully consider their investment strategies. Such a fluctuating market also opens up opportunities to take bigger risks and diversify your portfolios.
Methodology
We used stock screeners to look for companies that went public recently in the past 2 years, with a preference for latest IPOs. We then selected the 10 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q2 2024.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, with a focus on G-protein coupled receptors (GPCRs) as a therapeutic target class. It has a pipeline of promising drug candidates targeting various disease areas, including obesity, diabetes, and chronic obstructive pulmonary disease (COPD).
Structure Therapeutics is a promising company in the obesity treatment market with its oral drug GSBR-1290. It has several approved products for various conditions, including X-linked hypophosphatemia, mucopolysaccharidosis VII, long-chain fatty acid oxidation disorders, and homozygous familial hypercholesterolemia.
It recently announced positive results from phase IIa studies of its obesity drug GSBR-1290. The drug showed promising results in reducing weight and has the potential to become a leading oral treatment for obesity. Based on these results, Structure Therapeutics Inc. (NASDAQ:GPCR) plans to start a larger phase IIb study in Q4 2024.
The company plans to submit an application to the FDA in Q3 2024 to start a phase IIb study on GSBR-1290 for obesity. They also plan to start a study on GSBR-1290 for type II diabetes in the second half of 2024.
It exceeded earnings expectations in 3 out of the 4 last quarters, despite a loss per share of $0.18 in Q2 2024. Its pipeline of innovative drug candidates positions the company for significant growth in the obesity and diabetes markets. The company’s recent positive clinical trial results and development plans suggest a promising future.
Baron Health Care Fund stated the following regarding Structure Therapeutics Inc. (NASDAQ:GPCR) in its fourth quarter 2023 investor letter:
“Structure Therapeutics Inc. (NASDAQ:GPCR) is a biotechnology company dedicated to making oral small molecule medicines to target the obesity and diabetes market. Recent share weakness has been due to two large pharmaceutical acquisitions in the space: Roche’s purchase of Carmot and AstraZeneca’s in-licensing of Eccogene’s GLP-1 asset. These developments were followed by updates from Structure that implied it had a promising asset, but it might be inferior to Eli Lilly’s first-in-class product. Shares fell as analysts reduced the probability of success surrounding potential peak sales. We think it is too early to reach a final conclusion on the company’s oral small molecule GLP-1, as these data sets are limited in total sample size, and there are compelling arguments for both sides. Given how quickly this space changes and our smaller position sizing due to the aforementioned dynamics, we are monitoring our position and making decisions based on our evolving analysis. We initiated a small position in Structure Therapeutics Inc., a clinical-stage biotechnology company. Structure is developing an oral small molecule GLP-1 with once daily dosing. We think the GLP-1 class of obesity/diabetes drugs has the potential to be the largest drug class ever and that parts of the market will be particularly well suited to oral medications. Some people find oral medications more convenient than injectables, and oral small molecule drugs are cheaper and easier to manufacture than injectables, which could allow for lower pricing and greater access, particularly in international markets. Structure’s drug is still in its early phase of development, but there is reason to think that it could be successful. The drug was designed through the company’s structure-based drug discovery platform and was designed to selectively activate the G-protein signaling pathway, which should lead to a better efficacy/safety profile. In late September, Structure announced promising results from a Phase 1 multiple ascending dose study in non-diabetic overweight/obese individuals. Although there were only a few patients in the study, the drug impressively demonstrated reductions in mean body weight of up to 4.9% placebo-adjusted after 28 days, which would suggest a best-in-class profile. Then, in December, Structure announced results from its Phase 2a study, including a diabetic cohort and a non-diabetic overweight/obese cohort. The interim data from the obesity cohort continued to look competitive with 4.7% placebo-adjusted weight loss after 56 days. The diabetes data was somewhat underwhelming, with a 1.0% placebo-adjusted HbA1c reduction and 3.3% to 3.5% placebo-adjusted weight loss over 84 days (in comparison, Lilly’s orforglipron showed a 1.5% to 1.7% HbA1c reduction and 4.1% to 6.3% placebo-adjusted weight loss in a similar study). Structure is planning to study additional doses and titration regimens to optimize the drug’s profile in diabetes. Overall, we would characterize the early data as supportive of an active GLP-1 drug that has the potential to be among the leaders in the category. At this point we have a small position in the stock while we await more data to evaluate the competitiveness of Structure’s drug.”
Overall GPCR ranks 7th on our list of the best young stocks to buy now. While we acknowledge the growth potential of GPCR, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than GPCR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
